Article
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
EBioMedicine - 1 Apr 2024
Rey Verónica, Tornín Juan, Alba-Linares Juan Jose, Robledo Cristina, Murillo Dzohara, Rodríguez Aida, Gallego Borja, Huergo Carmen, Viera Cristina, Braña Alejandro, Astudillo Aurora, Heymann Dominique, Szuhai Karoly, Bovée Judith V M G, Fernández Agustín F, Fraga Mario F, Alonso Javier, Rodríguez René
Abstract excerpt
BACKGROUND: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes are among the most common mutations detected in chondrosarcomas and may represent a therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.